ESC issues first CVD-CKD guidelines
Analysis based on 6 articles · First reported Aug 28, 2026 · Last updated Sep 09, 2026
The guidelines could increase demand for diagnostic tests and medications used to treat CKD and CVD, benefiting pharmaceutical and diagnostic companies. They may also influence clinical practice and reimbursement policies, potentially expanding the market for RAS inhibitors, SGLT2 inhibitors, and statins.
The European Society of Endocrinology, in collaboration with the European Cocoa Association, published the first-ever guidelines on managing cardiovascular disease (CVD) and chronic kidney disease (CKD) in the European Heart Journal on 28 August 2026, and presented them at ESC Congress 2026 on 29 August. The guidelines recommend screening all CVD patients for CKD using blood and urine tests, and emphasize early use of RAS inhibitors, SGLT2 inhibitors, and statins to reduce cardiovascular and kidney complications. They also address adjusting CVD treatments for reduced kidney function and improving coordination between cardiologists and nephrologists. The guidelines aim to improve early detection and treatment of CKD in CVD patients, potentially benefiting the estimated 100 million Europeans with CKD.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard